Ceruloplasmin as a prognostic marker in patients with bile duct cancer

In Woong Han; Jin-Young Jang; Wooil Kwon; Taesung Park; Yongkang Kim; Kyoung Bun Lee; Sun-Whe Kim

doi:10.18632/oncotarget.15995

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Ceruloplasmin as a prognostic marker in patients with bile duct cancer

In Woong Han, Jin-Young Jang _, Wooil Kwon, Taesung Park, Yongkang Kim, Kyoung Bun Lee and Sun-Whe Kim

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:29028-29037. https://doi.org/10.18632/oncotarget.15995

Metrics: PDF 1779 views | HTML 2885 views | ?

Abstract

In Woong Han1,2, Jin-Young Jang2, Wooil Kwon2, Taesung Park3, Yongkang Kim3, Kyoung Bun Lee4, Sun-Whe Kim2

1Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-Gu, Seoul 06351, Korea

2Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Chongno-Gu, Seoul 110-744, Korea

3Department of Statistics, Seoul National University College of Natural Sciences, Gwanak-Gu, Seoul 08826, Korea

4Department of Pathology, Seoul National University College of Medicine, Chongno-Gu, Seoul 110-744, Korea

Correspondence to:

Jin-Young Jang, email: [email protected]

Keywords: bile duct, cancer, cholangiocarcinoma, biomarker, ceruloplasmin

Received: November 09, 2016 Accepted: February 06, 2017 Published: March 07, 2017

ABSTRACT

Background and Aims: Bile duct cancer is one of the lethal cancers, presenting difficulties in early diagnosis and limited treatment modalities. Despite current advances in biomarker research, most studies have been performed in Western populations. Therefore, the purpose of this study was to determine a prognostic marker for bile duct cancer, especially in Korean patients, whose incidence of bile duct cancer is high.

Results: Comparing cancer and normal bile duct tissue, we identified 29091 differentially expressed genes. CP, SCEL, and MUC16 had positive coefficients with a log2 ratio >1 for advanced T, N stage and perineural invasion cancer tissue. Strong immunohistochemical expression of ceruloplasmin was dominant in tumors with advanced T stage (p>0.999) and perineural invasion (p=0.316).

Patients and Methods: We performed tissue microarray experiment with 79 bile duct cancer tissue samples and 21 normal bile duct tissue samples. Candidate genes that has positive correlation with T, N stage and perineural invasion were drawn with multivariate analysis. Tissue expression of the genes was evaluated with an immunohistochemical study.

Conclusions: Ceruloplasmin is supposed to be related with advanced T stage and perineural invasion, having a possibility as a candidate prognostic marker for bile duct cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15995

Publication Alerts

Research Papers:

Ceruloplasmin as a prognostic marker in patients with bile duct cancer

Abstract